Rallybio Corporation — Company profile
Healthcare · Biotechnology · United States
Last price 15.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 81.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Details
| Name | Rallybio Corporation |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 7 |
| Founded | 2018 |
| Ipo Date | 2021-07-29 |
| Ceo | Stephen Uden |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 13.00 |
| Isin | US75120L2097 |
| Cusip | 75120L209 |
| Cik | 1739410 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Stephen Uden M.D., MBBS | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Martin W. MacKay Ph.D. | Co-Founder and Chairman |
Contact
| Address | 234 Church Street, New Haven, Connecticut 06510, United States |
| Phone | 203 859 3820 |
| Website | https://www.rallybio.com |